Lucira Health Inc. (NASDAQ:LHDX) traded with an addition of $0.01 to close at $0.13 on Thursday, an upside of 1.68 percent. An average of 904,344 shares of common stock have been traded in the last five days. There was a fall of -$0.0164 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 467,086 shares traded, while the 50-day average volume stands at 309,576.
LHDX stock has decreased by -68.62% in the last month. The company shares reached their 1-month lowest point of $0.1200 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.12 and a high of $9.30 in 52 weeks. It has reached a new high 1 time so far this year and lost -98.55% or -$8.4828 in price. In spite of this, the price is down -98.63% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
LHDX stock investors should be aware that Lucira Health Inc. (LHDX) stock had its last reported insider trading activity 9 days ago on Dec 20. In this transaction, the insider spent $682. Interim CFO, Narido Richard Clavano, disposed of 1,583 shares at a price of $0.36 on Dec 01. The insider now owns more than $570 worth of shares. Prior to that, Ex VP & Chief Quality Officer Kashmolah Ghazi went on to Sale 7,537 shares at $0.42 each on Nov 28. An amount of $3,166 was transacted.
Lucira Health Inc. (LHDX) has a trailing price-to-sales (P/S) ratio at 0.02, the price-to-book (PB) ratio at 0.08.
The quick ratio of Lucira Health Inc. for the three months ended September 29 was 0.80, and the current ratio was 1.50, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.48 and a total debt to equity ratio of 0.48 for the quarter ending September 29. Its gross profit as reported stood at $10.22 million compared to revenue of $93.06 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Lucira Health Inc.’s return on assets was -56.00%.
For the three-month period that ended September 29, Lucira Health Inc. had $29.41 million in total debt. The analyst consensus anticipated Lucira Health Inc.’s latest quarter earnings to come in at -$0.38 per share, but it turned out to be -$3.15, a -728.90% surprise. For the quarter, EBITDA amounted to -$124.36 million. Shareholders own equity worth $40.6 million.
From a technical analysis perspective, let’s take a brief look at Lucira Health Inc. (LHDX) price momentum. RSI 9-day as of the close on 28 December was 13.34%, suggesting the stock is oversold, with historical volatility in this time frame at 122.78%.
As of today, LHDX’s price is $0.1314 -11.42% or -$0.0164 from its 5-day moving average. LHDX is currently trading -66.53% lower than its 20-day SMA and -96.18% lower than its 100-day SMA. However, the stock’s current price level is -88.74% below the SMA50 and -95.95% below the SMA200.
The stochastic %K and %D were 2.76% and 3.22%, respectively, and the average true range (ATR) was 0.0421. With the 14-day stochastic at 3.79% and the average true range at 0.0509, the RSI (14) stands at 17.10%. The stock has reached -0.0272 on the 9-day MACD Oscillator while the 14-day reading was at -0.0709.
William Blair downgraded Lucira Health Inc. (NASDAQ: LHDX) to a a Mkt perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Lucira Health Inc. (LHDX) among analysts is Underweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell LHDX, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is LHDX’s price target for the next 12 months?
Analysts predict a range of price targets between $0.75 and $0.75, with a median target of $0.75. Taking a look at these predictions, the average price target given by analysts for Lucira Health Inc. (LHDX) stock is $0.75.